human papillomavirus 9-valent vaccine (Gardasil 9°) and cervical cancer A few cases of dysplasia prevented, but an increase in painful reactions

摘要

A human papillomavirus (HPV) vaccine containing 9 HPV genotypes (Gardasil 9°) has been authorised in the European Union. In France, the company that markets this vaccine expects it to replace the vaccine containing 4 genotypes (Gardasil0). A trial in about 14 000 women aged 16 to 26 years compared these two vaccines. The 9-valent vaccine appeared to reduce the number of diagnoses of high-grade cervical dysplasia caused by one of the additional genotypes: about 15 fewer cases per year per 10 000 vaccinated women who had not been infected with one of these genotypes before vaccination. The 9-valent vaccine provokes more, sometimes severe, injection site reactions, which could intensify existing misgivings about HPV vaccination.